查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864077

CAR-T細胞療法市場按適應症、細胞來源、代數、治療線、標靶抗原和最終用戶分類－2025-2032年全球預測

CAR T-cell Therapy Market by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CAR T 細胞療法市場將成長至 138.7 億美元，複合年成長率為 15.06%。

關鍵市場統計數據
基準年 2024 45.1億美元
預計年份：2025年 51.9億美元
預測年份 2032 138.7億美元
複合年成長率 (%) 15.06%

一份簡明扼要的CAR T細胞療法策略指南，整合了科學進展、生產實際情況、監管動態和商業性准入的考量。

CAR-T細胞療法領域正處於前沿免疫腫瘤學和複雜商業性運作的交匯點。本執行摘要整合了臨床進展、轉化創新、監管動態、日趨成熟的生產技術以及不斷變化的醫療服務模式，共同描繪了CAR-T領域的現狀。本摘要旨在指南企業主管、臨床負責人、投資者和政策制定者了解影響研發重點和營運決策的各項因素。

在簡要概述了治療機制和按適應症分類的臨床表現後，摘要轉向實際考量，例如生產能力、供應鏈韌性以及不斷發展的即時診療模式。文章始終強調將科學進步與商業性可行性聯繫起來的實用見解。文章揭示了模組化生產平台、抗原選擇策略和新一代構建體如何轉化為差異化的臨床特徵和新的應用模式。同時，支付方合作和真實世界證據的產生正成為影響藥物可近性和應用率的關鍵因素。

總的來說，本引言透過闡述技術、監管和經濟發展如何重塑相關人員的CAR-T 策略的整合過程，為後續章節提供了一個框架，從而支持有關投資、夥伴關係和營運設計的知情決策。

技術、監管、製造和商業性變革將共同重塑 CAR-T 療法的研發和病患獲取途徑。

CAR-T細胞療法正經歷一系列變革，這些變革超越了簡單的產品改進，從根本上改變了其研發和給藥的結構。載體工程、共刺激結構域選擇和抗原標靶化的進步，不僅拓展了治療範圍，也提升了安全性和持久性。這些技術進步與製造創新相輔相成，例如分散式和自動化平台，從而縮短了生產時間，並降低了每劑藥物的操作複雜性。隨著這些技術變革的推進，將集中式專業知識與即時治療相結合的新型商業模式正在湧現。

監管路徑也在同步調整，監管機構越來越願意考慮真實世界數據和適應性開發策略，以平衡快速應用和長期安全監測。同時，醫療系統正在重建基礎設施，以支持在傳統住院醫療機構之外開展CAR-T療法，而支付方也開始試驗按績效付費的合約模式，以使成本與臨床獲益相匹配。這些變化共同推動著治療模式從單一產品、高成本的干涉措施轉向更具擴充性、以循證醫學為導向的項目，這些項目優先考慮永續的療效和廣泛的患者覆蓋。能夠預見並應對這些轉變的相關人員將更有能力將科學領先優勢轉化為持續的臨床和商業性影響。

因應2025年關稅變化對供應鏈韌性、製造地選擇和臨床試驗物流的影響的營運和策略措施

美國將在2025年實施的新關稅為先進細胞療法的經濟和物流帶來了新的變數。對進口原料、一次性組件和某些生物加工設備徵收關稅，增加了上游成本，並導致供應商選擇的不確定性。這種情況促使製造商和臨床中心重新評估其籌資策略，尋找替代供應商，並考慮加強關鍵供應鏈的垂直整合。短期內，由於採購團隊需要評估關稅的影響並協商修改後的條款，因此採購週期預計將會延長。

除了採購之外，關稅帶來的成本壓力也會影響製造地決策。企業可能會加快對國內生產能力的投資，以降低跨境關稅風險。或者，他們可能會尋求區域合作，以實現關鍵流程的本地化，例如載體生產和填充表面處理工程。臨床試驗申辦方需要重新評估其預算假設，並可能優先考慮擁有附近製造地或冗餘供應設施的機構，以降低物流風險。同時，提供輸液服務的醫院和門診中心也需要調整其耗材庫存和資本設備採購計畫。

整體而言，2025年的關稅不會改變CAR-T療法的科學潛力，但會影響其商業營運決策。積極採取供應鏈多元化、在可行的情況下進行策略性本土化生產以及與供應商達成合作協議的相關人員，將能夠減輕中斷影響，確保患者治療的連續性，並保持研發和商業化的勢頭。

基於細分市場的洞察揭示了適應症、細胞來源、世代、治療線、抗原標靶和治療環境如何決定研發和商業化路徑

詳細的市場細分揭示了治療和給藥領域中細微的促進因素和清晰的機會點。依適應症分類，市場涵蓋白血病（細分為急性淋巴性白血病和急性骨髓性白血病）、多發性骨髓瘤和非何傑金氏淋巴瘤（瀰漫性大B細胞淋巴瘤、濾泡性淋巴瘤和套細胞淋巴瘤構成具體的臨床亞型）。每種適應症都有其獨特的療效預期、安全性考量和證據要件，這些都會影響臨床實驗設計和商業化策略。就細胞來源而言，異體療法能夠實現即時給藥並加快治療啟動速度，而自體療法在個人化生產與已確立的安全性和有效性記錄相符的領域仍然具有重要意義。

代間差異也影響臨床和營運模式。第一代產品旨在概念驗證；第二代產品整合了最佳化的共刺激結構域；第三代方法結合了多種訊號通路元件以提高持久性；第四代設計則整合了細胞激素表達和安全開關等功能，以拓展治療潛力。治療方案（第一線治療與復發/難治性治療）會影響臨床試驗終點和醫保支付方的討論，因為早期治療優先考慮安全性和長期療效，而復發/難治性治療則強調快速反應。標靶抗原的選擇（尤其是BCMA和CD19）持續推動著針對特異性適應症的治療策略和伴隨診斷的開發。最後，終端使用者群體——學術機構、醫院、門診腫瘤中心和專科診所——決定了培訓、基礎設施和診療路徑投資的有效性，從而影響部署順序和醫護人員之間的合作。

區域法規環境、生產策略和交付能力如何導致全球市場獲得 CAR-T 療法的機會差異

區域趨勢對監管預期、生產策略和醫療服務模式有著深遠的影響。在美洲，密集的專科醫療網路、歷來充滿活力的創投生態系統以及靈活的監管路徑，促進了早期臨床應用和商業化策略的實施，這些策略強調本土生產和真實世界證據的生成。同時，在歐洲、中東和非洲地區，管理體制的多樣性和報銷制度的不均衡，要求制定個性化的衛生經濟學論證和以社區為基礎的參與計劃，同時也為構建能夠服務於多個市場的區域性製造地提供了機會。

亞太地區正經歷快速的產能建設，國內對細胞治療平台的投資不斷增加，臨床試驗規模也在擴大，加速了病患招募和療效比較研究。各地區在基礎建設、勞動力發展和醫保報銷政策上的差異，影響藥物普及的速度和規模。因此，製造商正在根據區域特性建立製造地、監管策略和商業性夥伴關係，以最佳化產品上市順序和定價模式。包括許可、聯合開發和戰略生產聯盟在內的跨區域合作，正逐漸成為兼顧全球目標與本地實際情況和監管差異的切實可行的途徑。

透過製造規模、創新和一體化商業性支援來驅動競爭優勢的企業策略和合作模式

CAR-T療法生態系統中的領先機構正在尋求策略合作夥伴關係，以確保供應鏈安全並擴大臨床應用範圍，同時推動多樣化的架構設計、抗原標標靶化和生產方法。產業相關人員正在投資模組化、自動化生產平台，以縮短週期時間並提高可重複性，並加強與學術機構和契約製造的合作，以擴大產能。一些公司正透過專注於多抗原標靶化的下一代工程方法來實現差異化，以提高持久性、降低毒性並解決抗原逃脫問題。

同時，競爭格局日益聚焦於如何在專有平台優勢與加速臨床開發的合作模式之間取得平衡。許可和共同開發契約使新參與企業能夠利用成熟的載體技術和生產經驗，而現有企業則透過強力的證據生成和上市後監測來尋求臨床差異化。商業活動強調整合價值提案，將臨床培訓、報銷支援和結果追蹤相結合，以降低在醫療保健系統中實施的風險。因此，競爭優勢越來越取決於能否將科學差異化、可擴展的生產能力和切實的商業化支持結合在一起。

產業領導者行動計畫：將製造韌性、證據生成、支付方合作和擴大設施準備度聯繫起來，以加速永續獲取

行業領導者應優先採取一系列合作行動，將科學創新與營運擴充性和市場進入準備工作相結合。首先，投資建立靈活的生產架構，以支援自體和異體治療流程，從而能夠快速應對需求波動和關稅導致的採購變化。其次，建立健全的品質體系，並為關鍵試劑和一次性組件提供冗餘供應，以最大限度地減少生產中斷，確保患者治療計劃的順利進行。第三，透過與治療中心和註冊機構合作，加速產生真實世界證據，記錄長期治療結果和安全性訊號，這些證據可作為醫保報銷談判的基礎。

同時，企業應與支付方建立夥伴關係，探索與持續療效指標掛鉤的按績效付費合約和風險分擔模式，這將有助於在臨床第一線儘早推廣應用。在臨床方面，企業應擴大訓練計畫和認證途徑，以便在更多醫院和門診腫瘤中心安全用藥，從而縮短治療啟動時間，改善病患就醫途徑。最後，企業應在生產和監管方面採取策略性在地化措施，以平衡成本、上市速度和本地市場准入要求。這些措施將增強企業韌性，使產品價值與醫療系統需求相契合，並加速將科研成果轉化為病患獲益。

採用透明的混合方法，結合相關人員訪談、文獻綜述、監管審查和營運案例研究，得出切實可行的建議。

本研究整合了一級資訊來源和二級資訊來源，以現代科學和商業性實踐為基礎，得出有證據支持的結論。一級資訊來源包括對臨床研究人員、生產專業人員、支付方和各治療中心的營運負責人進行的結構化訪談，以收集關於產能限制、供應鏈風險和實施障礙的實地觀點。二手資料分析涵蓋了同行評審文獻、監管指導文件、會議報告和公司披露資訊，以綜合考慮臨床療效、安全性趨勢和技術進步。

此分析方法結合了主題綜合和比較營運評估，以識別產能瓶頸和策略應對措施。製造規模擴大和分散式生產模式的案例研究為切實可行的建議奠定了基礎。調查方法始終強調資料限制的透明度，例如不同適應症的臨床證據成熟度差異以及不斷變化的監管環境。對區域監管差異和供應鏈變異性的考量指導了情境規劃和風險緩解提案。倫理考量和以病人為中心的結果是解釋框架的核心，研究團隊採取了嚴格的檢驗程序，以確保其對決策者的可信度和相關性。

策略要務綜合分析，重點闡述了製造業韌性、證據生成和支付方合作對於實現科學潛力的重要性。

總之，CAR-T細胞療法正處於一個關鍵的轉折點，只有科學創新、生產能力和商業策略能夠協同運作，才能為更廣泛的患者群體帶來福祉。儘管建築工程和下一代設計領域的技術進步不斷拓展著治療的可能性，但供應鏈以及營運對政策變化的反應速度將決定這些治療方法何時能夠成為常規治療方案。監管的靈活性以及支付方圍繞基於結果的模式的積極參與，是將臨床獲益轉化為永續可及性的關鍵槓桿。

從設想到實踐，需要對生產韌性、證據產生和臨床準備進行協同投資，並積極與包括監管機構、支付方和醫療服務提供相關人員的利益相關者合作。能夠將技術差異化與務實的營運設計和區域策略相結合的機構，將獲得最大的臨床和商業性效益。最終，CAR-T療法的未來取決於分子創新以及將療法傳遞給患者的系統的韌性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大患者獲得異基因現成CAR-T療法的機會
  • 雙靶向和強化型CAR-T細胞構建體的出現，提高了安全性
  • 整合自動化製造平台以縮短CAR-T生產時間
  • 引入新型基因編輯工具以最大程度地減少CAR T細胞的脫靶效應
  • 開發結合CAR-T細胞療法和免疫查核點抑制劑的聯合治療
  • 在產生真實世界證據以指導CAR-T細胞療法的定價和報銷策略方面取得進展
  • 監管協調工作旨在加速CAR-T細胞療法的全球核准進程。
  • 在臨床中心採用照護現場生產模式，以提高治療的可近性。
  • 將CAR-T細胞療法的適應症擴大至全球固體癌治療領域。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依適應症分類的 CAR-T 細胞療法市場

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
  • 多發性骨髓瘤
  • 非何傑金氏淋巴瘤
    • 瀰漫性大B細胞淋巴瘤
    • 濾泡性淋巴瘤
    • 套細胞淋巴瘤

第9章 CAR-T細胞療法市場（依細胞來源分類）

  • 同種異體移植
  • 自有住房

第10章 CAR-T細胞療法市場（按世代分類）

  • 第一代
  • 第四代
  • 第二代
  • 第三代

第11章 CAR-T細胞療法市場按治療線分類

  • 一線治療
  • 復發/難治性

第12章 CAR-T細胞療法市場（以標靶抗原分類）

  • BCMA
  • CD19

第13章：依最終用戶分類的CAR-T細胞療法市場

  • 學術研究機構
  • 醫院
  • 門診腫瘤中心
  • 專科診所

14. 各地區的 CAR-T 細胞療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：按組別分類的CAR-T細胞療法市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國CAR-T細胞療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Legend Biotech Corporation
    • Miltenyi Biotec GmbH
    • Allogene Therapeutics, Inc.
    • Cellectis SA
    • Autolus Therapeutics plc
    • Poseida Therapeutics, Inc.
Product Code: MRR-1E2F1ED7E6AA

The CAR T-cell Therapy Market is projected to grow by USD 13.87 billion at a CAGR of 15.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.51 billion
Estimated Year [2025] USD 5.19 billion
Forecast Year [2032] USD 13.87 billion
CAGR (%) 15.06%

A concise strategic orientation to CAR T-cell therapy integrating scientific progress, manufacturing realities, regulatory dynamics, and commercial access considerations

The landscape of CAR T-cell therapy sits at the intersection of cutting-edge immuno-oncology science and complex commercial execution. This executive summary synthesizes clinical progress, translational innovations, regulatory momentum, manufacturing maturation, and shifting care delivery models that collectively define the current state of CAR T field. It is intended to orient executives, clinical leaders, investors, and policy makers to the forces shaping development priorities and operational decisions.

Beginning with a succinct review of therapeutic mechanisms and indication-specific clinical performance, the summary transitions to pragmatic considerations such as manufacturing capacity, supply chain resilience, and evolving site-of-care dynamics. Throughout, emphasis rests on actionable insights that link scientific advances to commercial feasibility. The narrative highlights how modular manufacturing platforms, antigen selection strategies, and next-generation constructs are translating into differentiated clinical profiles and new usage paradigms. In parallel, payor engagement and real-world evidence generation are emerging as critical determinants of access and uptake.

Taken together, the introduction frames subsequent sections by clarifying how discrete technological, regulatory, and economic developments are converging to reshape CAR T strategy across stakeholders, supporting informed decisions about investment, partnership, and operational design.

How technical, regulatory, manufacturing, and commercial shifts are jointly reconfiguring CAR T development pathways and patterns of patient access

CAR T-cell therapy is undergoing a series of transformative shifts that extend beyond incremental product improvements to alter the structure of development and delivery. Advances in vector engineering, costimulatory domain selection, and antigen targeting are expanding therapeutic applicability while simultaneously influencing safety and durability profiles. These technical evolutions are complemented by manufacturing innovations such as decentralized and automated platforms that shorten production timelines and lower per-dose operational complexity. As these technical shifts progress, they create opportunities for novel commercial models that blend centralized expertise with point-of-care delivery.

Regulatory pathways are adapting in parallel, with agencies showing increasing willingness to consider real-world evidence and adaptive development strategies that balance expedited access with long-term safety monitoring. Meanwhile, health systems are recalibrating infrastructure to support CAR T administration outside of traditional inpatient settings, and payors are experimenting with outcome-based contracting to align cost and clinical benefit. Taken together, these shifts are driving a transition from single-product, high-cost interventions toward more scalable, evidence-driven programs that prioritize durable outcomes and broader patient access. Stakeholders that anticipate and align with these shifts will be better positioned to convert scientific leadership into sustained clinical and commercial impact.

Operational and strategic responses to 2025 tariff shifts that reshape supply chain resilience, manufacturing footprint decisions, and clinical trial logistics

The introduction of new United States tariff measures in 2025 has introduced a tangible variable into the economics and logistics of advanced cell therapies. Tariffs applied to imported raw materials, single-use components, and specific bioprocessing equipment increase upstream costs and create uncertainty in supplier selection. This dynamic incentivizes manufacturers and clinical centers to re-evaluate sourcing strategies, explore alternative suppliers, and consider increased vertical integration of critical supply chains. In the near term, procurement cycles lengthen as contracting teams assess tariff impacts and negotiate revised terms.

Beyond procurement, tariff-driven cost pressures influence decisions around manufacturing footprint. Organizations may accelerate investments in domestic manufacturing capacity to reduce exposure to cross-border duties, or they may pursue regional partnerships that localize key steps such as vector production and fill-finish operations. Clinical trial sponsors will need to revisit budgeting assumptions and may prioritize sites with proximate manufacturing or supply redundancy to mitigate logistical risk. In parallel, hospitals and outpatient centers that provide infusion services must adapt planning for consumable inventory and capital equipment procurement.

Taken together, tariffs in 2025 do not change the scientific promise of CAR T therapies, but they do alter operational calculus. Stakeholders who adopt proactive supply chain diversification, strategic onshoring where feasible, and collaborative contracting with suppliers will reduce disruption and preserve treatment continuity for patients while maintaining momentum in development and commercialization.

Segmentation-driven insights that reveal how indication, cell source, generation, therapeutic line, antigen targeting, and care settings define development and commercialization pathways

Detailed segmentation uncovers nuanced drivers and distinct opportunity spaces across therapeutic and delivery domains. By indication the market spans Leukemia, which itself is subdivided into Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, Multiple Myeloma, and Non Hodgkin Lymphoma with Diffuse Large B Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma representing specific clinical subtypes; each indication carries unique response expectations, safety considerations, and evidentiary needs that influence trial design and commercialization strategy. Considering cell source, therapies derived from Allogeneic sources offer the promise of off-the-shelf dosing and faster time-to-treatment, while Autologous approaches remain prominent where individualized manufacturing aligns with established safety and efficacy precedents.

Generational differentiation also shapes clinical and operational profiles; First Generation constructs established proof of concept, Second Generation products introduced optimized costimulatory domains, Third Generation approaches combine multiple signaling elements for enhanced persistence, and Fourth Generation designs incorporate engineered functionalities such as cytokine expression or safety switches to broaden therapeutic potential. Line of therapy segmentation, including Frontline versus Relapsed Refractory use, dictates trial endpoints and payer conversations since earlier-line adoption prioritizes safety and long-term benefit whereas relapsed refractory contexts emphasize rapid response. Target antigen selection, notably BCMA and CD19, continues to drive indication-specific strategies and companion diagnostics development. Finally, end user segmentation across Academic Research Institutes, Hospitals, Outpatient Oncology Centers, and Specialty Clinics determines where investments in training, infrastructure, and care pathways will be most impactful, influencing rollout sequencing and provider partnerships.

How regional regulatory environments, manufacturing strategies, and care delivery capacity are directing differentiated CAR T access across global markets

Regional dynamics exert a powerful influence on regulatory expectations, manufacturing strategy, and care delivery models. In the Americas, dense networks of specialized treatment centers, a historically active venture ecosystem, and flexible regulatory pathways have catalyzed early clinical adoption and commercialization strategies that emphasize domestic manufacturing and real-world evidence generation. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes and heterogeneous reimbursement systems that require tailored health economic arguments and localized engagement plans, while also offering opportunities for regional manufacturing hubs that can serve multiple markets.

Asia-Pacific exhibits rapid capacity building, increasing domestic investment into cell therapy platforms, and an expanding pool of clinical trial sites that can accelerate patient accrual and comparative effectiveness research. Differences in infrastructure, workforce training, and reimbursement policy across these regions shape the pace and scale of access; as a result, manufacturers are adopting region-specific manufacturing footprints, regulatory strategies, and commercial partnerships to optimize launch sequencing and pricing models. Cross-regional collaboration, including licensing, co-development, and strategic manufacturing alliances, emerges as a practical pathway to reconcile global ambition with local realities and regulatory nuance.

Corporate strategies and collaborative models that drive competitive advantage through manufacturing scale, construct innovation, and integrated commercial support

Leading organizations in the CAR T ecosystem are advancing diversified portfolios across construct design, antigen targeting, and manufacturing modalities while pursuing strategic alliances to secure supply chains and broaden clinical reach. Industry participants are investing in modular, automated manufacturing platforms to reduce cycle times and improve reproducibility, and they are forging partnerships with academic centers and contract manufacturing organizations to expand capacity. Several companies are differentiating through next-generation engineering approaches that focus on enhancing persistence, reducing toxicities, and enabling multi-antigen targeting to address antigen escape.

At the same time, competitive dynamics reflect a balance between proprietary platform advantages and collaborative models that accelerate clinical development. Licensing agreements and co-development arrangements enable newer entrants to leverage established vector and manufacturing know-how, while incumbents seek to protect clinical differentiation through robust evidence generation and post-market surveillance. Commercial activities emphasize integrated value propositions that combine clinical training, reimbursement support, and outcomes tracking to de-risk adoption for health systems. As a result, competitive advantage increasingly derives from the ability to align scientific differentiation with scalable manufacturing and pragmatic commercialization support.

Action plans for industry leaders to link manufacturing resilience, evidence generation, payer engagement, and expanded site readiness to accelerate sustainable access

Industry leaders should prioritize a set of coordinated actions that connect scientific innovation with operational scalability and market access readiness. First, invest in flexible manufacturing architectures that support both autologous and allogeneic workflows, enabling rapid response to demand shifts and tariff-induced sourcing variability. Second, embed robust quality systems and supply redundancy for critical reagents and single-use components to minimize production interruptions and preserve patient schedules. Third, accelerate generation of real-world evidence by partnering with treatment centers and registries to document long-term outcomes and safety signals that underpin reimbursement discussions.

In parallel, companies should cultivate payer partnerships that explore outcome-based contracting and risk-sharing models aligned to durable response metrics, facilitating earlier adoption in frontline settings. From a clinical perspective, expand training programs and accreditation pathways to enable safe administration across a broader range of hospitals and outpatient oncology centers, thereby reducing time-to-treatment and improving patient access. Finally, adopt strategic regionalization for manufacturing and regulatory engagement that balances cost, speed-to-market, and local market access imperatives. These combined steps will strengthen resilience and align product value with health system needs, accelerating the conversion of scientific promise into patient benefit.

A transparent mixed-methods approach combining stakeholder interviews, literature synthesis, regulatory review, and operational case studies to inform practical recommendations

This research synthesized primary and secondary sources to produce evidence-based insights grounded in contemporary scientific and commercial practice. Primary inputs included structured interviews with clinical investigators, manufacturing experts, payers, and operational leaders across treatment centers to capture on-the-ground perspectives about capacity constraints, supply chain risks, and adoption barriers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to triangulate clinical efficacy, safety trends, and technological advancements.

Analytical methods combined thematic synthesis with comparative operational assessment to identify capacity bottlenecks and strategic responses. Case studies of manufacturing scale-up and decentralized production models informed practical recommendations. Throughout the methodology, emphasis was placed on transparency around data limitations, including the variable maturity of clinical evidence across indications and the evolving regulatory landscape. Sensitivity to regional regulatory differences and supply chain volatility guided scenario planning and risk mitigation suggestions. Ethical considerations and patient-centric outcomes remain central to the interpretive framework, and the research team employed rigorous validation steps to ensure credibility and relevance for decision-makers.

Synthesis of strategic imperatives showing that scientific promise requires manufacturing resilience, evidence generation, and payer engagement to achieve broader access

In conclusion, CAR T-cell therapy stands at a decisive inflection point where scientific innovation, manufacturing capability, and commercial strategy must align to deliver broader patient impact. Technical progress in construct engineering and next-generation designs continues to expand therapeutic potential, while operational responses to supply chain and policy changes will determine the pace at which those therapies become routine care options. Regulatory flexibility and payer willingness to engage around outcomes-based models are critical levers to translate clinical benefit into sustainable access.

Moving from promise to practice requires coordinated investments in manufacturing resilience, evidence generation, and clinical site readiness, together with proactive stakeholder engagement across regulators, payers, and providers. Organizations that synchronize technical differentiation with pragmatic operational design and regional strategy will capture the greatest clinical and commercial upside. Ultimately, the future of CAR T depends not only on molecular innovation but equally on the robustness of the systems that deliver these therapies to patients in need.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of allogeneic off-the-shelf CAR T therapies to broaden patient access
  • 5.2. Emergence of dual-target and armored CAR T constructs for enhanced safety profiles
  • 5.3. Integration of automated manufacturing platforms to reduce CAR T production times
  • 5.4. Implementation of novel gene editing tools to minimize off-target effects in CAR T cells
  • 5.5. Development of combination regimens pairing CAR T-cell therapy with immune checkpoint inhibitors
  • 5.6. Advancements in real-world evidence generation to inform pricing and reimbursement strategies for CAR T
  • 5.7. Regulatory harmonization efforts to accelerate global approval pathways for CAR T-cell treatments
  • 5.8. Adoption of point-of-care manufacturing models within clinical centers to improve treatment accessibility
  • 5.9. Expansion of CAR T-cell therapy indications into solid tumor oncology pipelines worldwide

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CAR T-cell Therapy Market, by Indication

  • 8.1. Leukemia
    • 8.1.1. Acute Lymphoblastic Leukemia
    • 8.1.2. Acute Myeloid Leukemia
  • 8.2. Multiple Myeloma
  • 8.3. Non Hodgkin Lymphoma
    • 8.3.1. Diffuse Large B Cell Lymphoma
    • 8.3.2. Follicular Lymphoma
    • 8.3.3. Mantle Cell Lymphoma

9. CAR T-cell Therapy Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. CAR T-cell Therapy Market, by Generation

  • 10.1. First Generation
  • 10.2. Fourth Generation
  • 10.3. Second Generation
  • 10.4. Third Generation

11. CAR T-cell Therapy Market, by Line Of Therapy

  • 11.1. Frontline
  • 11.2. Relapsed Refractory

12. CAR T-cell Therapy Market, by Target Antigen

  • 12.1. BCMA
  • 12.2. CD19

13. CAR T-cell Therapy Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Hospitals
  • 13.3. Outpatient Oncology Centers
  • 13.4. Specialty Clinics

14. CAR T-cell Therapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. CAR T-cell Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. CAR T-cell Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Novartis AG
    • 17.3.2. Gilead Sciences, Inc.
    • 17.3.3. Bristol-Myers Squibb Company
    • 17.3.4. Johnson & Johnson
    • 17.3.5. Legend Biotech Corporation
    • 17.3.6. Miltenyi Biotec GmbH
    • 17.3.7. Allogene Therapeutics, Inc.
    • 17.3.8. Cellectis S.A.
    • 17.3.9. Autolus Therapeutics plc
    • 17.3.10. Poseida Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CAR T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. GCC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 322. GCC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 323. GCC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 324. GCC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 325. GCC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 326. GCC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 327. GCC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 328. GCC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 329. GCC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
  • TABLE 330. GCC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
  • TABLE 331. GCC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 332. GCC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MI